Navigation Links
Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
Date:9/16/2008

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today that Dr. Joseph Kovalchin will make a poster presentation titled "Evidence of Specific T-cell Priming from the First-in-Man Single Ascending Dose Study of Peptide Copolymer PI-2301 for the Treatment of Multiple Sclerosis " on Thursday, September 18th from 3:30 - 5:00 p.m. in Exhibit Hall 220C, at the Palais Des Congres de Montreal, Canada at the World Congress on Treatment and Research in Multiple Sclerosis. The Congress is expected to attract over 3,500 participants from around the globe -- clinicians, clinical researchers, and basic scientists. This will be the largest single gathering of MS clinicians and researchers in 2008.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.

For information please contact Tom Mathers at (617) 715-8000 or tom.mathers@peptimmune.com.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Announces First Close of Series D Private Financing
2. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
3. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Robert W. Baird Conference
5. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
6. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
8. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
10. Volcano Presentation at Thomas Weisel Conference to Be Webcast
11. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication Process (Extrusion, Injection ... to 2026", published by MarketsandMarkets, the global market size was USD 645.4 Million ... an of CAGR of 6.2% between 2016 and 2026. ... ... , , ...
(Date:12/7/2016)... 2016  Muse bio, a privately-held company leading the ... Dr. Kevin Ness has been appointed Chief ... Kevin succeeds Muse bio,s founding CEO ... Science Officer as well as remains Slade Professor, Chemical ... Center at the RAS Energy Institute at the University ...
(Date:12/7/2016)... ... December 07, 2016 , ... Cambrian Innovation ... industrial facilities, today announced that one of the nation’s fastest growing craft breweries, ... water-energy purchase agreement (WEPA). Under the WEPA, a first for the industrial wastewater ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... program for SmartBiome -- a novel metagenomic deep-sequencing research platform. SmartBiome combines ... detection of hundreds of different genes. The selective early access program is ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
(Date:11/16/2016)... CLARA, Calif. , Nov. 16, 2016 ... enhancing user experience and security for consumer electronics, ... for the financial and retail industry, today announced ... secure and convenient way to authenticate users of ... uses Sensory,s TrulySecure™ software which requires ...
Breaking Biology News(10 mins):